

Chapter-7

References

Abd-Ellah, H. S., et al. (2016). "Novel 1, 3, 4-oxadiazole/oxime hybrids: Synthesis, docking studies and investigation of anti-inflammatory, ulcerogenic liability and analgesic activities." Bioorganic Chemistry 69: 48-63.

Abdelrahman, M. H., et al. (2017). "Synthesis, biological evaluation, docking study and ulcerogenicity profiling of some novel quinoline-2-carboxamides as dual COXs/LOX inhibitors endowed with anti-inflammatory activity." European Journal of Medicinal Chemistry 127: 972-985.

Ahmad, S., et al. (2018). "Ameliorative effect of beraprost sodium on celecoxib induced cardiotoxicity in rats." Iranian journal of pharmaceutical research: IJPR 17: 155.

Akhter, M., et al. (2011). "Synthesis and biological evaluation of 2, 5-disubstituted 1, 3, 4-oxadiazole derivatives with both COX and LOX inhibitory activity." Journal of Enzyme Inhibition and Medicinal Chemistry 26: 767-776.

Alharbi, K. S., et al. (2023). Pathophysiology and pathogenesis of inflammation. Recent Developments in Anti-Inflammatory Therapy, Elsevier: 11 1-9.

Aliabadi, A., et al. (2023). "Dual COX-2/15-LOX inhibitors: A new avenue in the prevention of cancer." European Journal of Medicinal Chemistry: 115866.

Amir, M., et al. (2007). "Non-carboxylic analogues of naproxen: design, synthesis, and pharmacological evaluation of some 1, 3, 4-oxadiazole/thiadiazole and 1, 2, 4-triazole derivatives." Archiv der Pharmazie: An International Journal Pharmaceutical and Medicinal Chemistry 340: 577-585.

Amir, M. and K. Shikha (2004). "Synthesis and anti-inflammatory, analgesic, ulcerogenic and lipid peroxidation activities of some new 2-[(2, 6-dichloroanilino) phenyl] acetic acid derivatives." European Journal of Medicinal Chemistry 39: 535-545.

Ananda Kumar, C., et al. (2007). "Synthesis and evaluation of 1-benzhydryl-sulfonyl-piperazine derivatives as inhibitors of MDA-MB-231 human breast cancer cell proliferation." Medicinal Chemistry Research 16: 179-187.

Arfeen, M., et al. (2024). "Design, classification, and adverse effects of NSAIDs: A review on recent advancements." Bioorganic & Medicinal Chemistry: 117899.

Badri, W., et al. (2016). "Encapsulation of NSAIDs for inflammation management: overview, progress, challenges and prospects." International journal of pharmaceutics 51: 757-773.

Bala, S., et al. (2013). "Anti-inflammatory, analgesic evaluation and molecular docking studies of N-phenyl anthranilic acid-based 1, 3, 4-oxadiazole analogues." Journal of Chemistry 2013: 412053.

Banerjee, A. G., et al. (2016). "Design, synthesis, evaluation and molecular modelling studies of some novel 5, 6-diphenyl-1, 2, 4-triazin-3 (2H)-ones bearing five-member heterocyclic moieties as potential COX-2 inhibitors: A hybrid pharmacophore approach." Bioorganic Chemistry 69: 102-120.

Banerjee, A. G., et al. (2015). "Synthesis, characterization, evaluation and molecular dynamics studies of 5, 6-diphenyl-1, 2, 4-triazin-3 (2H)-one derivatives bearing 5-substituted 1, 3, 4-oxadiazole as potential anti-inflammatory and analgesic agents." European Journal of Medicinal Chemistry 101: 81-95.

Bashir, B., et al. (2022). "Assessing p-tolyloxy-1, 3, 4-oxadiazole acetamides as lipoxygenase inhibitors assisted by in vitro and in silico studies." Bioorganic Chemistry 129: 106144.

Bhardwaj, A., et al. (2017). "In situ click chemistry generation of cyclooxygenase-2 inhibitors." Nature communications 8: 1.

Bitto, A., et al. (2012). "Flavocoxid, a dual inhibitor of COX-2 and 5-LOX of natural origin, attenuates the inflammatory response and protects mice from sepsis." Critical Care 16: 1-12.

Chandrasekharan, J. A. and N. Sharma-Walia (2015). "Lipoxins: nature's way to resolve inflammation." Journal of inflammation research: 181-192.

Charlier, C. and C. Michaux (2003). "Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs." European Journal of Medicinal Chemistry 38: 645-659.

Che, X.-H., et al. (2016). "Dual inhibition of COX-2/5-LOX blocks colon cancer proliferation, migration and invasion in vitro." Oncology reports 35: 1680-1688.

Dadashpour, S., et al. (2015). "Design, synthesis and in vitro study of 5, 6-diaryl-1, 2, 4-triazine-3-ylthioacetate derivatives as COX-2 and β -amyloid aggregation inhibitors." Archiv der Pharmazie 348: 179-187.

de Gaetano, G., et al. (2003). "Prevention of thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors." Trends in pharmacological sciences 24: 245-252.

Deshmukh, R. and A. G. Sharma, PL (2013). "P1-392: Licofelone: A dual COX/5-LOX inhibitor attenuates intracerebroventricular streptozotocin-induced cognitive deficit, oxidative stress and neuro-inflammatory cytokines in rats." Alzheimer's & Dementia 9: P302-P302.

Dhawan, S., et al. (2018). "Synthesis, computational studies and antiproliferative activities of coumarin-tagged 1, 3, 4-oxadiazole conjugates against MDA-MB-231 and MCF-7 human breast cancer cells." Bioorganic & Medicinal Chemistry 26: 5612-5623.

DiMartino, M., et al. (1987). "The pharmacology of arachidonic acid-induced rat paw edema." Agents and Actions 21: 303-305.

Du, L., et al. (2023). "Design, synthesis, and biological evaluation of dual-target COX-2/5-LOX inhibitors for the treatment of inflammation." Medicinal Chemistry Research 32: 218-238.

El-Agrody, A., et al. (2001). "Heteroaromatization with 4-Hydroxycoumarin Part II: Synthesis of Some New Pyrano [2, 3-d] pyrimidines,[1, 2, 4] triazolo [1, 5-c] pyrimidines and Pyrimido [1, 6-b]-[1, 2, 4] triazine Derivatives." Molecules 6: 519-527.

Ertaş, M., et al. (2022). "Synthesis of some 5, 6-diaryl-1, 2, 4-triazine derivatives and investigation of their cyclooxygenase (COX) inhibitory activity." Phosphorus, Sulfur, and Silicon and the Related Elements 197: 1123-1135.

Fatima, S., et al. (2023). "Design, synthesis, and biological evaluation of morpholinopyrimidine derivatives as anti-inflammatory agents." RSC Advances 13: 19119-19129.

Fiorucci, S., et al. (2001). "Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?" Biochemical pharmacology 62: 1433-1438.

Fomenko, I., et al. (2015). "Changes of nitric oxide system and lipid peroxidation parameters in the digestive system of rats under conditions of acute stress, and use of nonsteroidal anti-inflammatory drugs." Current Issues in Pharmacy and Medical Sciences 28: 37-41.

Fretz, H., et al. (2013). "Identification of 2-(2-(1-naphthoyl)-8-fluoro-3, 4-dihydro-1 h-pyrido [4, 3-b] indol-5 (2 h)-yl) acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) antagonist." Journal of Medicinal Chemistry 56: 4899-4911.

Gedawy, E. M., et al. (2020). "Design, synthesis and biological evaluation of novel pyrazole sulfonamide derivatives as dual COX-2/5-LOX inhibitors." European Journal of Medicinal Chemistry 189: 112066.

Ghanim, A. M., et al. (2021). "Novel 1, 2, 4-triazine-quinoline hybrids: The privileged scaffolds as potent multi-target inhibitors of LPS-induced inflammatory response via dual COX-2 and 15-LOX inhibition." European Journal of Medicinal Chemistry 219: 113457.

Ghosh, R., et al. (2015). "NSAIDs and cardiovascular diseases: role of reactive oxygen species." Oxidative medicine and cellular longevity 2015: 536962.

Gilbert, N. C., et al. (2011). "The structure of human 5-lipoxygenase." Science 331: 217-219.

Goossens, L., et al. (2007). "COX-2/5-LOX dual acting anti-inflammatory drugs in cancer chemotherapy." Current topics in medicinal chemistry 7: 283-296.

Grover, J., et al. (2015). "2, 5-Diaryl-1, 3, 4-oxadiazoles as selective COX-2 inhibitors and anti-inflammatory agents." RSC Advances 5: 45535-45544.

Hamoud, M. M., et al. (2022). "Design and synthesis of novel 1, 3, 4-oxadiazole and 1, 2, 4-triazole derivatives as cyclooxygenase-2 inhibitors with anti-inflammatory and antioxidant activity in LPS-stimulated RAW264. 7 macrophages." Bioorganic Chemistry 124: 105808.

- Hawkey, C. (1999). "COX-2 inhibitors." The lancet 353: 307-314.
- Hla, T., et al. (1999). "Cyclooxygenase-1 and-2 isoenzymes." The international journal of biochemistry & cell biology 31: 551-557.
- Hsu, K.-C., et al. (2020). "A site-moiety map and virtual screening approach for discovery of novel 5-LOX inhibitors." Scientific reports 10: 10510.
- Irannejad, H., et al. (2014). "Synthesis, docking simulation, biological evaluations and 3D-QSAR study of 5-Aryl-6-(4-methylsulfonyl)-3-(methylthio)-1, 2, 4-triazine as selective cyclooxygenase-2 inhibitors." Bioorganic & Medicinal Chemistry 22: 865-873.
- Jain, A., et al. (2020). "Piperazine: A Promising Scaffold with Analgesic and Anti-inflammatory Potential." Drug Research 71: 62-72.
- Jayashankar, B., et al. (2009). "Synthesis and pharmacological evaluation of 1, 3, 4-oxadiazole bearing bis (heterocycle) derivatives as anti-inflammatory and analgesic agents." European Journal of Medicinal Chemistry 44: 3898-3902.
- Kannan, M. M. and S. D. Quine (2013). "Ellagic acid inhibits cardiac arrhythmias, hypertrophy and hyperlipidaemia during myocardial infarction in rats." Metabolism 62: 52-61.
- Kattan, W. E. and J. F. Hancock (2020). "RAS Function in cancer cells: translating membrane biology and biochemistry into new therapeutics." Biochemical Journal 477: 2893-2919.
- Kaur, S., et al. (2018). "Design and synthesis of aza-/oxa heterocycle-based conjugates as novel anti-inflammatory agents targeting cyclooxygenase-2." ACS omega 3: 5825-5845.
- Khan, S. A., et al. (2015). "Synthesis, spectroscopic (UV-vis and GIAO NMR), crystallographic and theoretical studies of triazine heterocyclic derivatives." Journal of Molecular Structure 1096: 29-37.
- Khoshneviszadeh, M., et al. (2013). "Design, synthesis and biological evaluation of novel anti-cytokine 1, 2, 4-triazine derivatives." Bioorganic & Medicinal Chemistry 21: 6708-6717.
- Kode, J., et al. (2020). "Synthesis, biological evaluation, and molecular docking analysis of phenstatin based indole linked chalcones as anticancer agents and tubulin polymerization inhibitors." Bioorganic Chemistry 105: 104447.
- Kumar, A., et al. (2020). "Exploring the molecular approach of COX and LOX in Alzheimer's and Parkinson's disorder." Molecular biology reports 47: 9895-9912.
- Kumar, C., et al. (2017). "Synthesis and anti-inflammatory activity of 1-benzhydryl-piperazine urea derivatives." Journal of Applicable Chemistry 6: 282-290.

- Kumar, M., et al. (2016). "Baicalein protects isoproterenol induced myocardial ischemic injury in male Wistar rats by mitigating oxidative stress and inflammation." Inflammation Research 65: 613-622.
- Kumar, M., et al. (2016). "Animal models of myocardial infarction: Mainstay in clinical translation." Regulatory Toxicology and Pharmacology 76: 221-230.
- Kumar, M., et al. (2017). "Molecular and biochemical evidence on the protective effects of quercetin in isoproterenol-induced acute myocardial injury in rats." Journal of biochemical and molecular toxicology 31: 1-8.
- Kuna, L., et al. (2019). "Peptic ulcer disease: a brief review of conventional therapy and herbal treatment options." Journal of clinical medicine 8: 179.
- Lee, S. H., et al. (2004). "Dual inhibition of cyclooxygenases-2 and 5-lipoxygenase by deoxypodophyllotoxin in mouse bone marrow-derived mast cells." Biological and Pharmaceutical Bulletin 27: 786-788.
- Leone, S., et al. (2007). "Dual acting anti-inflammatory drugs." Current topics in medicinal chemistry 7: 265-275.
- Leung, K. S., et al. (2021). "Enrichment of alpha-linolenic acid in rodent diet reduced oxidative stress and inflammation during myocardial infarction." Free Radical Biology and Medicine 162: 53-64.
- Lewis, T. A., et al. (2004). "5-Lipoxygenase inhibitors with histamine H1 receptor antagonist activity." Bioorganic & medicinal chemistry letters 14: 2265-2268.
- Libby, P. (2007). "Inflammatory mechanisms: the molecular basis of inflammation and disease." Nutrition reviews 65: S140-S146.
- Libby, P. (2012). "Inflammation in atherosclerosis." Arteriosclerosis, thrombosis, and vascular biology 32: 2045-2051.
- Liebrechts, T., et al. (2007). "Immune activation in patients with irritable bowel syndrome." Gastroenterology 132: 913-920.
- Manju, S. (2020). "Identification and development of thiazole leads as COX-2/5-LOX inhibitors through in-vitro and in-vivo biological evaluation for anti-inflammatory activity." Bioorganic Chemistry 100: 103882.
- Manju, S., et al. (2018). "Safer anti-inflammatory therapy through dual COX-2/5-LOX inhibitors: A structure-based approach." European Journal of Pharmaceutical Sciences 121: 356-381.
- Maqbool, M., et al. (2020). "Diphenyl triazine hybrids inhibit α -synuclein fibrillogenesis: Design, synthesis and in vitro efficacy studies." European Journal of Medicinal Chemistry 207: 112705.

Marciniak, A., et al. (2022). "The 2-hydroxy-3-(4-aryl-1-piperazinyl) propyl Phthalimide Derivatives as Prodrugs—Spectroscopic and Theoretical Binding Studies with Plasma Proteins." International Journal of Molecular Sciences 23: 7003.

Martel-Pelletier, J., et al. (2003). "Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs." Annals of the rheumatic diseases 62: 501-509.

Martinez, B. K. and C. M. White (2018). "The emerging role of inflammation in cardiovascular disease." Annals of Pharmacotherapy 52: 801-809.

Marzouk, A. A., et al. (2021). "Design, synthesis, biological evaluation, and computational studies of novel thiazolo-pyrazole hybrids as promising selective COX-2 inhibitors: Implementation of apoptotic genes expression for ulcerogenic liability assessment." Bioorganic Chemistry 111: 104883.

Marzouk, B., et al. (2010). "Screening of analgesic and anti-inflammatory activities of *Citrullus colocynthis* from southern Tunisia." Journal of Ethnopharmacology 128: 15-19.

Medzhitov, R. (2008). "Origin and physiological roles of inflammation." Nature 454: 428-435.

Miller, K., et al. (2013). "Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer." Prostate cancer and prostatic diseases 16: 187-192.

Misra, U., et al. (1996). "Biologically active indolylmethyl-1, 3, 4-oxadiazoles, 1, 3, 4-thiadiazoles, 4H--1, 3, 4-triazoles and 1, 2, 4-triazines." European Journal of Medicinal Chemistry 31: 629-634.

Mittal, R., et al. (2022). "An overview of novel bioactive compounds with potent anti-inflammatory activity via dual COX-2 and 5-LOX enzyme inhibition." Current Bioactive Compounds 18: 4-21.

Mittal, R., et al. (2024). "Novel Dual COX-2/5-LOX Inhibitory Activity by Chalcone Derivatives: A Safe and Efficacious Anti-inflammatory Agent." Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 23: 174-186.

Mohammed, A., et al. (2011). "Chemoprevention of colon and small intestinal tumorigenesis in APCMin/+ mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention." Cancer prevention research 4: 2015-2026.

Mohassab, A. M., et al. (2021). "New quinoline/1, 2, 4-triazole hybrids as dual inhibitors of COX-2/5-LOX and inflammatory cytokines: Design, synthesis, and docking study." Journal of Molecular Structure 1244: 130948.

Mukherjee, D., et al. (2001). "Risk of cardiovascular events associated with selective COX-2 inhibitors." Jama 286: 954-959.

- Mukhopadhyay, N., et al. (2023). "Natural product-driven dual COX-LOX inhibitors: Overview of recent studies on the development of novel anti-inflammatory agents." Heliyon 9.
- Mukhopadhyay, S., et al. (2021). "The metabolic landscape of RAS-driven cancers from biology to therapy." Nature cancer 2: 271-283.
- Mullick, P., et al. (2009). "Synthesis of 1, 2, 4-triazine derivatives as potential anti-anxiety and anti-inflammatory agents." Acta Pol. Pharm. Drug Res 66: 379-385.
- Narayana, B., et al. (2005). "Synthesis of Some New 2-(6-Methoxy-2-Naphthyl)-5-Aryl-1, 3, 4-Oxadiazoles as Possible Non-steroidal Anti-inflammatory and Analgesic Agents." Archiv der Pharmazie: An International Journal Pharmaceutical and Medicinal Chemistry 338: 373-377.
- Naveena, S., et al. (2010). "STRUCTURAL CHEMISTRY COMMUNICATIONS." Structural Chemistry 1: 33-36.
- Nicolaides, D. N., et al. (1998). "Synthesis and biological evaluation of several coumarin-4-carboxamidoxime and 3-(coumarin-4-yl)-1, 2, 4-oxadiazole derivatives." European Journal of Medicinal Chemistry 33: 715-724.
- Okunishi, K. and M. Peters-Golden (2011). "Leukotrienes and airway inflammation." Biochimica et Biophysica Acta (BBA)-General Subjects 1810: 1096-1102.
- Omar, F. A., et al. (1996). "Design, synthesis and antiinflammatory activity of some 1, 3, 4-oxadiazole derivatives." European Journal of Medicinal Chemistry 31: 819-825.
- Orafaie, A., et al. (2020). "An overview of lipoxygenase inhibitors with approach of in vivo studies." Prostaglandins & Other Lipid Mediators 148: 106411.
- Padejjar Vasantha, S., et al. (2019). "Novel arylpyridine-based 1, 3, 4-oxadiazoles: Synthesis, antibacterial, and anti-inflammatory evaluation." Journal of the Chinese Chemical Society 66: 638-650.
- Pergola, C. and O. Werz (2010). "5-Lipoxygenase inhibitors: a review of recent developments and patents." Expert opinion on therapeutic patents 20: 355-375.
- Philoppes, J. N., et al. (2023). "Novel N-methylsulfonyl-indole derivatives: biological activity and COX-2/5-LOX inhibitory effect with improved gastro protective profile and reduced cardio vascular risks." Journal of Enzyme Inhibition and Medicinal Chemistry 38: 246-266.
- Pillai, L., et al. (2010). "GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin." Current medical research and opinion 26: 1055-1063.
- Poeckel, D. and C. D. Funk (2010). "The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease." Cardiovascular research 86: 243-253.

Pratyusha, V. A., et al. (2018). "Ras hyperactivation versus overexpression: Lessons from Ras dynamics in *Candida albicans*." Scientific reports 8: 5248.

Prince, P. S. M. and A. J. Roy (2013). "p-Coumaric acid attenuates apoptosis in isoproterenol-induced myocardial infarcted rats by inhibiting oxidative stress." International Journal of Cardiology 168: 3259-3266.

Qiu, X., et al. (2021). "Design, synthesis and anti-inflammatory study of novel N-heterocyclic substituted Aloe-emodin derivatives." Chemical Biology & Drug Design 97: 358-371.

Rådmark, O., et al. (2015). "5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease." Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids 1851: 331-339.

Ramakrishna, K. and S. Krishnamurthy (2022). "Indole-3-carbinol ameliorated the isoproterenol-induced myocardial infarction via multimodal mechanisms in Wistar rats." Natural Product Research 36: 6044-6049.

Ramakrishna, K. and S. Krishnamurthy (2023). "Indole-3-carbinol ameliorated the neurodevelopmental deficits in neonatal anoxic injury in rats." International Journal of Developmental Neuroscience 83: 31-43.

Ranneh, Y., et al. (2017). "Crosstalk between reactive oxygen species and pro-inflammatory markers in developing various chronic diseases: a review." Applied Biological Chemistry 60: 327-338.

Roy, L. D., et al. (2024). "Piperazine tethered heterocyclic hybrids: Synthesis, characterization, and in vitro studies from potent proteinase inhibitors to antiproliferative activity." European Journal of Medicinal Chemistry Reports 10: 100132.

Rudrapal, M., et al. (2023). "Dual synergistic inhibition of COX and LOX by potential chemicals from Indian daily spices investigated through detailed computational studies." Scientific reports 13: 8656.

Saraf, P., et al. (2022). "Novel 5, 6-diphenyl-1, 2, 4-triazine-3-thiol derivatives as dual COX-2/5-LOX inhibitors devoid of cardiotoxicity." Bioorganic Chemistry 129: 106147.

Sharma, A., et al. (2020). "An overview of piperazine scaffold as promising nucleus for different therapeutic targets." Current Pharmaceutical Design 26: 4373-4385.

Sharma, P., et al. (2019). "Novel molecular hybrids of n-benzylpiperidine and 1, 3, 4-oxadiazole as multitargeted therapeutics to treat alzheimer's disease." ACS Chemical Neuroscience 10: 4361-4384.

Sharma, V. and M. Khan (2003). "Prodrugs and mutual prodrugs: synthesis of some new pyrazolone and oxadiazole analogues of a few non-steroidal anti-inflammatory drugs." Die Pharmazie-An International Journal of Pharmaceutical Sciences 58: 99-103.

Shen, F.-Q., et al. (2017). "Synthesis of novel hybrids of pyrazole and coumarin as dual inhibitors of COX-2 and 5-LOX." Bioorganic & medicinal chemistry letters 27: 3653-3660.

Shrivastava, S. K., et al. (2017). "Design, synthesis, and biological evaluation of some novel indolizine derivatives as dual cyclooxygenase and lipoxygenase inhibitor for anti-inflammatory activity." Bioorganic & Medicinal Chemistry 25: 4424-4432.

Siddiqui, S. Z., et al. (2014). "Synthesis, pharmacological evaluation, molecular docking and cytotoxicity studies on some N-substituted 5-[(4-chlorophenoxy) methyl]-1, 3, 4-oxadiazole-2-yl-2-sulfanyl acetamides." Indo Am J Pharm Res 2014; 4: 3603-3617.

Singh, P., et al. (2015). "Indole based peptidomimetics as anti-inflammatory and anti-hyperalgesic agents: dual inhibition of 5-LOX and COX-2 enzymes." European Journal of Medicinal Chemistry 97: 104-123.

Sinha, S., et al. (2019). "Chalcone-Thiazole Hybrids: Rational Design, Synthesis, and Lead Identification against 5-Lipoxygenase." ACS medicinal chemistry letters 10: 1415-1422.

Smith, W. L., et al. (2000). "Cyclooxygenases: structural, cellular, and molecular biology." Annual review of biochemistry 69: 145-182.

Sokolowska, M., et al. (2021). "Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I." Allergy 76: 114-130.

Srivastava, R. K., et al. (2021). Compositions and methods for reducing cell viability, Google Patents.

Stenvinkel, P., et al. (2005). "IL-10, IL-6, and TNF- α : central factors in the altered cytokine network of uremia—the good, the bad, and the ugly." Kidney international 67: 1216-1233.

Szandruk-Bender, M., et al. (2021). "Novel 1, 3, 4-oxadiazole derivatives of pyrrolo [3, 4-d] pyridazinone exert anti-inflammatory activity without acute gastrotoxicity in the carrageenan-induced rat paw edema test." Journal of Inflammation Research: 5739-5756.

Szczukowski, Ł., et al. (2020). "Design, synthesis and comprehensive investigations of pyrrolo [3, 4-d] pyridazinone-based 1, 3, 4-oxadiazole as new class of selective cox-2 inhibitors." International Journal of Molecular Sciences 21: 9623.

Tripathi, A., et al. (2020). "Design, synthesis, and biological evaluation of ferulic acid based 1, 3, 4-oxadiazole hybrids as multifunctional therapeutics for the treatment of Alzheimer's disease." Bioorganic Chemistry 95: 103506.

Tripathi, A., et al. (2019). "Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1, 3, 4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease." European Journal of Medicinal Chemistry 183: 111707.

- Ugbogu, E. A., et al. (2024). "Phytochemical characterization, anti-diarrhoeal, analgesic, anti-inflammatory activities and toxicity profile of *Ananas comosus* (L.) Merr (pineapple) leaf in albino rats." Journal of Ethnopharmacology 319: 117224.
- Ullah, S. H., et al. (2023). "Blocking the major inflammatory pathways by newly synthesized thiadiazine derivatives via in-vivo, in-vitro and in-silico mechanism." Bioorganic Chemistry 140: 106760.
- Valente, S., et al. (2014). "1, 3, 4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells." Journal of Medicinal Chemistry 57: 6259-6265.
- Vichai, V. and K. Kirtikara (2006). "Sulforhodamine B colorimetric assay for cytotoxicity screening." Nature protocols 1: 1112-1116.
- Vinegar, R., et al. (1969). "Biphasic development of carrageenin edema in rats." Journal of pharmacology and experimental therapeutics 166: 96-103.
- Waiker, D. K., et al. (2023). "Development and Evaluation of Some Molecular Hybrids of N-(1-Benzylpiperidin-4-yl)-2-((5-phenyl-1, 3, 4-oxadiazol-2-yl) thio) as Multifunctional Agents to Combat Alzheimer's Disease." ACS omega 8: 9394-9414.
- Wang, B., et al. (2021). "Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets." Signal transduction and targeted therapy 6: 94.
- Wang, J.-J., et al. (2022). "Research progress on the synthesis and pharmacology of 1, 3, 4-oxadiazole and 1, 2, 4-oxadiazole derivatives: a mini review." Journal of Enzyme Inhibition and Medicinal Chemistry 37: 2304-2319.
- Wang, T., et al. (2015). "Synthesis and vasorelaxation evaluation of novel biphenyl-furocoumarin derivatives." Medicinal Chemistry Research 24: 2417-2431.
- Wang, W.-d., et al. (2009). "Apoptosis of human Burkitt's lymphoma cells induced by 2-N, N-diethylaminocarbonyloxymethyl-1-diphenylmethyl-4-(3, 4, 5-trimethoxybenzoyl) piperazine hydrochloride (PMS-1077)." Archives of pharmacal research 32: 1727-1736.
- Wechsler, M. E. (2018). "Current and emerging biologic therapies for asthma and COPD." Respiratory care 63: 699-707.
- Yadav, N., et al. (2017). "Development of 1, 3, 4-oxadiazole thione based novel anticancer agents: Design, synthesis and in-vitro studies." Biomedicine & Pharmacotherapy 95: 721-730.
- Ye, Y., et al. (2005). "Dual inhibition of 5-LOX and COX-2 suppresses colon cancer formation promoted by cigarette smoke." Carcinogenesis 26: 827-834.
- Zhang, F., et al. (2023). "Dual-target inhibitors based on COX-2: a review from medicinal chemistry perspectives." Future Medicinal Chemistry 15: 2209-2233.

Zhang, X., et al. (2021). "Effect of chromium supplementation on hs-CRP, TNF- α and IL-6 as risk factor for cardiovascular diseases: A meta-analysis of randomized-controlled trials." Complementary therapies in clinical practice 42: 101291.

Zhao, H., et al. (2021). "Inflammation and tumor progression: signaling pathways and targeted intervention." Signal transduction and targeted therapy 6: 263.